BACKGROUND: Identified as a biomarker of altered calcium-phosphorus metabolism in chronic kidney disease, fibroblast growth factor 23 (FGF-23) can also be used as a biomarker of risk for cardiovascular disease in the general population. However, it is crucial to first evaluate the reproducibility (reliability) of plasma FGF-23 concentrations. METHODS: We assessed the reliability of plasma FGF-23 concentrations using replicate blood samples taken four months apart of 207 participants from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. RESULTS: Plasma FGF-23 concentrations at baseline (geometric mean: 24.7 RU/mL; 95% confidence interval [CI] in RU/mL: 21.8-27.9) were not significantly different from those measured four months later (geometric mean: 23.7 RU/mL; 95% CI in RU/mL: 20.6-27.1; P = 0.42). The intraclass correlation coefficients were 0.69 (95% CI: 0.62-0.76) for all; 0.64 (95% CI: 0.50-0.75) for men and 0.73 (95% CI: 0.64-0.81) for women. CONCLUSIONS: Plasma FGF-23 concentrations showed good reliability over time. Our findings suggest that in epidemiological studies, a single plasma FGF-23 measurement may be sufficient to derive the relative risk in prospective cohort studies.
BACKGROUND: Identified as a biomarker of altered calcium-phosphorus metabolism in chronic kidney disease, fibroblast growth factor 23 (FGF-23) can also be used as a biomarker of risk for cardiovascular disease in the general population. However, it is crucial to first evaluate the reproducibility (reliability) of plasma FGF-23 concentrations. METHODS: We assessed the reliability of plasma FGF-23 concentrations using replicate blood samples taken four months apart of 207 participants from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. RESULTS: Plasma FGF-23 concentrations at baseline (geometric mean: 24.7 RU/mL; 95% confidence interval [CI] in RU/mL: 21.8-27.9) were not significantly different from those measured four months later (geometric mean: 23.7 RU/mL; 95% CI in RU/mL: 20.6-27.1; P = 0.42). The intraclass correlation coefficients were 0.69 (95% CI: 0.62-0.76) for all; 0.64 (95% CI: 0.50-0.75) for men and 0.73 (95% CI: 0.64-0.81) for women. CONCLUSIONS: Plasma FGF-23 concentrations showed good reliability over time. Our findings suggest that in epidemiological studies, a single plasma FGF-23 measurement may be sufficient to derive the relative risk in prospective cohort studies.
Authors: Matthew Schenk; Fabian Eichelmann; Matthias B Schulze; Natalia Rudovich; Andreas F Pfeiffer; Romina di Giuseppe; Heiner Boeing; Krasimira Aleksandrova Journal: Biomark Med Date: 2019-06-03 Impact factor: 2.851
Authors: Romina di Giuseppe; Tilman Kühn; Frank Hirche; Brian Buijsse; Jutta Dierkes; Andreas Fritsche; Rudolf Kaaks; Heiner Boeing; Gabriele I Stangl; Cornelia Weikert Journal: PLoS One Date: 2015-07-20 Impact factor: 3.240